Thermo Fisher Scientific Inc. filed its Form 10-Q with the SEC on October 30, 2026, covering the quarterly period ended September 26, 2026, reporting total revenues of $12,137 million for the three months ended that date.

Key Highlights

  • Quarterly revenues: Total revenues for the three months ended September 26, 2026 were $12,137 million, compared with $11,122 million in the same period of 2025, according to the filing.
  • Nine-month revenues: For the nine months ended September 26, 2026, total revenues were $35,136 million, up from $32,341 million in the prior-year period, the company disclosed.
  • Quarterly net income: Net income attributable to Thermo Fisher Scientific Inc. was $1,721 million for the quarter, versus $1,616 million in Q3 2025.
  • Diluted EPS: Diluted earnings per share attributable to Thermo Fisher Scientific Inc. were $4.64 for Q3 2026, compared with $4.27 in Q3 2025.
  • Operating income: Operating income for the three-month period was $2,263 million, up from $1,941 million a year earlier, according to the filing.
  • Shares outstanding: As of September 26, 2026, the registrant reported 370,515,868 shares of common stock outstanding.
  • Total assets: Total assets were $114,233 million as of September 26, 2026, compared with $110,343 million as of December 31, 2025.

Thermo Fisher Scientific Reports Q3 2026 Financial Results

According to the Form 10-Q filed with the SEC, Thermo Fisher Scientific Inc. (NYSE:TMO) reported total revenues of $12,137 million for the three months ended September 26, 2026, consisting of product revenues of $6,753 million and service revenues of $5,384 million. In the comparable prior-year quarter, product revenues were $6,489 million and service revenues were $4,633 million, the filing disclosed.

The company reported operating income of $2,263 million for Q3 2026, after total costs and operating expenses of $9,874 million, which included restructuring and other costs of $199 million. Net income attributable to Thermo Fisher Scientific Inc. for the quarter was $1,721 million, with basic earnings per share of $4.65 and diluted earnings per share of $4.64, as stated in the filing. For the nine months ended September 26, 2026, net income attributable to the company was $5,108 million, with diluted earnings per share of $13.75.

On the balance sheet, goodwill stood at $54,263 million as of September 26, 2026, up from $49,362 million at December 31, 2025, and acquisition-related intangible assets, net, were $18,077 million. Long-term obligations were $39,108 million, while cash and cash equivalents were $5,461 million at the end of the quarter, compared with $9,852 million at year-end 2025. Total shareholders' equity attributable to Thermo Fisher Scientific Inc. was $54,761 million, the filing reported. The company had 75,995,868 shares held as treasury stock at cost of $26,408 million as of September 26, 2026.

What Was Disclosed

Thermo Fisher Scientific Inc. filed its quarterly report on Form 10-Q for the period ended September 26, 2026, disclosing revenues, operating income, net income, earnings per share, balance sheet data, and segment information for the three and nine months ended that date.